Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IRGM1 supports host defense against intracellular bacteria through suppression of type I interferon in mice
Prashant Rai, … , Gregory A. Taylor, Michael B. Fessler
Prashant Rai, … , Gregory A. Taylor, Michael B. Fessler
Published September 12, 2023
Citation Information: J Clin Invest. 2023;133(21):e171982. https://doi.org/10.1172/JCI171982.
View: Text | PDF
Research Letter Immunology Infectious disease

IRGM1 supports host defense against intracellular bacteria through suppression of type I interferon in mice

  • Text
  • PDF
Abstract

Authors

Prashant Rai, Martin Sharpe, Charan K. Ganta, Paul J. Baker, Katrin D. Mayer-Barber, Brian E. Fee, Gregory A. Taylor, Michael B. Fessler

×

Figure 1

IFN-I induces susceptibility to bacterial infection in Irgm1–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
IFN-I induces susceptibility to bacterial infection in Irgm1–/– mice.
(A...
(A) Survival curves after infection with M. tuberculosis (n = 7–10) and L. monocytogenes (n = 4–5). Spleen CFU on day 21 after S. typhimurium infection (n = 4–9). (B) Liver on day 3 after L. monocytogenes infection stained for TUNEL and DAPI. Scale bar: 200 μm. (C) Quantification of TUNEL+ foci (n = 3). (D) Peritoneal lavage CFU at 4 hours, day 1, and day 3 after L. monocytogenes (n = 4–8). (E) Isolated F4/80hi peritoneal macrophages exposed to L. monocytogenes were permeabilized for CFU count after 24 hours. (F) Macrophages were stained for L. monocytogenes and lysosome (LAMP1) at 6 hours and quantified for volumetric pixels of L. monocytogenes that were LAMP1+ (n = 32 images). (G) Percentage GFP+ after 4-hour infection by GFP-tagged L. monocytogenes (n = 9–10). (H) Neutrophil and (I) F4/80hi tissue macrophage numbers in infected peritoneal lavage (n = 7–11). (J) Representative plot showing depletion of CD11b+F4/80hi macrophages at 24 hours. (K) CFU in peritoneal cavity (PerC), liver, and spleen on day 3 after L. monocytogenes (n = 5–8). Data are shown as the mean ± SEM. #P < 0.08, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (1-way ANOVA with Tukey’s adjustment for A and C–I or Student’s t test for K).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts